Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

At the least, the new 7.2mg results point to scope for hiking the semaglutide dose in CagriSema to chase down that weight-loss target. The company is also running a phase 3b trial of 7.2mg ...

Maintaining a healthy weight is good for your body and can also help with self-esteem. If you’ve been trying to lose weight, ...

Dr. George Carroll runs BeSlimMD, a private weight loss clinic in Maitland. He has been helping patients lose weight for more ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

Millions of Brits are now eligible for the appetite-suppressing jabs which can come with unpleasant side effects - but NHS rationing means only a tiny fraction will be prescribed them ...

The readout comes on the heels of CagriSema’s disappointing Phase III performance, where it missed Novo’s projection of 25% ...

Veru (VERU) announced positive topline results from the Phase 2b QUALITY clinical study. The Phase 2b QUALITY clinical study was ...

NPA chairman Nick Kaye told the PA news agency that while obesity is "one of the biggest challenges facing" the UK, they are ...

William Wood, an analyst from B.Riley Financial, maintained the Buy rating on Veru (VERU – Research Report). The associated price target ...

Findings showed semaglutide 7.2mg demonstrated a statistically significant and superior weight loss compared with placebo at week 72. Topline data were announced from a phase 3b trial evaluating ...

Treatment with the highest dose of investigational injectable amycretin -- a unimolecular GLP-1 and amylin receptor agonist -- yielded a 22% weight loss after 36 weeks in a phase Ib/IIa trial, said ...